Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 34,547 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $75.51, for a total transaction of $2,608,643.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NBIX stock traded up $1.06 on Thursday, hitting $79.95. 11,764 shares of the company’s stock traded hands, compared to its average volume of 972,405. The company has a debt-to-equity ratio of 0.96, a quick ratio of 8.61 and a current ratio of 8.79. Neurocrine Biosciences, Inc. has a one year low of $64.72 and a one year high of $126.98. The firm has a market cap of $7.18 billion, a P/E ratio of 363.68 and a beta of 1.73.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, April 29th. The company reported ($1.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The business had revenue of $138.40 million for the quarter, compared to the consensus estimate of $136.77 million. During the same period in the prior year, the business posted ($0.47) EPS. Neurocrine Biosciences’s revenue for the quarter was up 94.7% on a year-over-year basis. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post -0.24 EPS for the current year.
NBIX has been the topic of several research reports. ValuEngine upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, February 8th. Barclays restated a “buy” rating and set a $110.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, March 29th. JPMorgan Chase & Co. cut shares of Neurocrine Biosciences from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $97.00 to $100.00 in a research report on Wednesday, January 23rd. Oppenheimer raised their price objective on shares of Neurocrine Biosciences from $105.00 to $110.00 and gave the company an “outperform” rating in a research report on Wednesday, March 13th. Finally, Needham & Company LLC cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $103.42.
Institutional investors have recently made changes to their positions in the business. Eaton Vance Management grew its holdings in Neurocrine Biosciences by 20.8% in the 4th quarter. Eaton Vance Management now owns 129,434 shares of the company’s stock worth $9,243,000 after acquiring an additional 22,280 shares during the last quarter. NumerixS Investment Technologies Inc grew its holdings in Neurocrine Biosciences by 75.2% in the 4th quarter. NumerixS Investment Technologies Inc now owns 3,300 shares of the company’s stock worth $226,000 after acquiring an additional 1,416 shares during the last quarter. Brinker Capital Inc. bought a new stake in Neurocrine Biosciences in the 4th quarter worth $705,000. Voloridge Investment Management LLC bought a new stake in Neurocrine Biosciences in the 4th quarter worth $4,331,000. Finally, LPL Financial LLC bought a new stake in Neurocrine Biosciences in the 4th quarter worth $278,000. 99.57% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 34,547 Shares” was posted by Highlight Press and is owned by of Highlight Press. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://highlightpress.com/2019/05/16/neurocrine-biosciences-inc-nbix-insider-haig-p-bozigian-sells-34547-shares.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Read More: Diversification in Your Portfolio
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.